Stuart A. Arbuckle

2014

In 2014, Stuart A. Arbuckle earned a total compensation of $15.2M as EVP & Chief Commercial Officer at Vertex Pharmaceuticals, a 215% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$675,000
Option Awards$4,044,646
Salary$600,000
Stock Awards$9,865,110
Other$12,857
Total$15,197,613

Arbuckle received $9.9M in stock awards, accounting for 65% of the total pay in 2014.

Arbuckle also received $675K in non-equity incentive plan, $4M in option awards, $600K in salary and $12.9K in other compensation.

Rankings

In 2014, Stuart A. Arbuckle's compensation ranked 223rd out of 13,032 executives tracked by ExecPay. In other words, Arbuckle earned more than 98.3% of executives.

ClassificationRankingPercentile
All
223
out of 13,032
98th
Division
Manufacturing
84
out of 4,966
98th
Major group
Chemicals And Allied Products
33
out of 1,686
98th
Industry group
Drugs
27
out of 1,365
98th
Industry
Pharmaceutical Preparations
25
out of 1,043
98th
Source: SEC filing on April 28, 2017.

Arbuckle's colleagues

We found four more compensation records of executives who worked with Stuart A. Arbuckle at Vertex Pharmaceuticals in 2014.

2014

Jeffrey Leiden

Vertex Pharmaceuticals

Chief Executive Officer

2014

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2014

Jeffrey Chodakewitz

Vertex Pharmaceuticals

Chief Medical Officer

2014

Kenneth Horton

Vertex Pharmaceuticals

Chief Legal Officer

News

You may also like